Kailera’s oral GLP-1 asset sees 11% weight loss, hits goals in Chinese phase 3 obesity and diabetes trials

Health tech companies rush to market 'GLP-1 ready' products as weight loss drug trend grows

This article from Verge's Optimizer newsletter examines how health tech companies are marketing products specifically to GLP-1 drug users (p

GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

Triple hormone drug retatrutide shows promise for diabetes and weight loss in Lancet trial

A new triple hormone drug called retatrutide, which mimics GLP-1, GIP, and glucagon, has shown promising results in a Lancet-published trial

GSK initiates phase III programme for novel type 2 diabetes medication, Syncria® (albiglutide)

Daily weight loss pill available in UK pharmacies from today

Eli Lilly's experimental GLP-1 drug achieves 28% average weight loss, raising safety questions

Eli Lilly has released data showing its experimental GLP-1 weight-loss drug enables patients to lose an average of 28% of their body weight,